[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL140239A0 - Anti-angiogenic proteins and methods of use thereof - Google Patents

Anti-angiogenic proteins and methods of use thereof

Info

Publication number
IL140239A0
IL140239A0 IL14023999A IL14023999A IL140239A0 IL 140239 A0 IL140239 A0 IL 140239A0 IL 14023999 A IL14023999 A IL 14023999A IL 14023999 A IL14023999 A IL 14023999A IL 140239 A0 IL140239 A0 IL 140239A0
Authority
IL
Israel
Prior art keywords
methods
angiogenic proteins
angiogenic
proteins
Prior art date
Application number
IL14023999A
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Publication of IL140239A0 publication Critical patent/IL140239A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
IL14023999A 1998-06-17 1999-06-17 Anti-angiogenic proteins and methods of use thereof IL140239A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8968998P 1998-06-17 1998-06-17
US12617599P 1999-03-25 1999-03-25
PCT/US1999/013737 WO1999065940A1 (en) 1998-06-17 1999-06-17 Anti-angiogenic proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
IL140239A0 true IL140239A0 (en) 2002-02-10

Family

ID=26780845

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14023999A IL140239A0 (en) 1998-06-17 1999-06-17 Anti-angiogenic proteins and methods of use thereof

Country Status (8)

Country Link
EP (1) EP1086129A1 (en)
JP (3) JP2002517999A (en)
KR (1) KR100682666B1 (en)
CN (1) CN1309663A (en)
AU (1) AU753249B2 (en)
CA (1) CA2331332A1 (en)
IL (1) IL140239A0 (en)
WO (1) WO1999065940A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US7387779B2 (en) 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US6759047B1 (en) 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
JP2003519630A (en) * 2000-01-07 2003-06-24 ベス イスラエル ディーコネス メディカル センター Anti-angiogenic proteins and fragments thereof and methods of use
WO2001059112A1 (en) * 2000-02-10 2001-08-16 Zymogenetics, Inc. Anti-angiogenic intestinal peptides, zdint5
US7342002B2 (en) 2000-08-03 2008-03-11 The Johns Hopkins University Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen
EP1371377B1 (en) 2001-01-05 2009-10-28 Viromed Limited Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof
WO2002083072A2 (en) * 2001-04-13 2002-10-24 Boyce Thompson Institute For Plant Research Methods and compositions for stable transgenic plant pharmaceuticals and their use as contraceptives
CN100447155C (en) * 2001-05-23 2008-12-31 中国科学院上海上海生命科学研究院 Recombinant human endothelial growth arrestin with activity of inhibiting endothelial cell growth
AU2002329643B2 (en) * 2001-07-27 2006-11-16 University Of Kansas Medical Center Crystallized structure of type IV collagen NC1 domain hexamer
WO2004098526A2 (en) 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2006073970A2 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
JP4843767B2 (en) * 2005-08-31 2011-12-21 国立大学法人 岡山大学 Angiogenesis inhibitors using cancer cell-specific gene expression
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
CN101962404A (en) * 2010-06-17 2011-02-02 中国热带农业科学院热带生物技术研究所 Protein used for treating hemangioma
JP6073888B2 (en) * 2011-08-17 2017-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレート Transferrin-tumstatin fusion protein, method for producing the same, and method for using the same
WO2014180288A1 (en) * 2013-05-06 2014-11-13 中国药科大学 Fusion protein having dual-functions for inhibiting angiogenesis in tumour microenvironment and activating adaptive immune response and gene and use thereof
CN111087477B (en) * 2020-01-03 2021-10-08 四川大学华西医院 GBM-7S (alpha 1) -NC1 (alpha 3) fusion protein and preparation method thereof
CN113735966B (en) * 2021-09-29 2022-11-01 陕西巨子生物技术有限公司 Anti-tumor recombinant collagen and preparation method and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876332A (en) * 1987-10-08 1989-10-24 Regents Of The Univeristy Of Minnesota Polypeptides with type IV collagen activity
US5354690A (en) * 1989-07-07 1994-10-11 Karl Tryggvason Immunological methods for the detection of the human type IV collagen α5 chain
US5114840A (en) * 1989-07-07 1992-05-19 Karl Tryggvason Method for determining the nucleotide sequence of a novel α5(IV) chain of human type IV collagen
US5082926A (en) * 1989-12-14 1992-01-21 Regents Of The University Of Minnesota Polypeptide with type iv collagen cell adhesion, spreading and motility activity
US5081031A (en) * 1989-12-14 1992-01-14 Regents Of The University Of Minnesota Synthetic polypeptide with type iv collagen activity
US5424408A (en) * 1990-11-30 1995-06-13 Yale University α-3 chain type IV collagen polynucleotides
US5731192A (en) * 1993-08-27 1998-03-24 Yale University Collagen COL4A6: gene, protein and method of detecting collagen deficiency
US5567609A (en) * 1994-06-30 1996-10-22 University Of Kansas Medical Center Use of isolated domains of type IV collagen to modify cell and tissue interactions

Also Published As

Publication number Publication date
CA2331332A1 (en) 1999-12-23
AU753249B2 (en) 2002-10-10
JP2008019271A (en) 2008-01-31
KR20010053018A (en) 2001-06-25
JP2002517999A (en) 2002-06-25
CN1309663A (en) 2001-08-22
JP2008301823A (en) 2008-12-18
KR100682666B1 (en) 2007-02-15
EP1086129A1 (en) 2001-03-28
AU4575599A (en) 2000-01-05
WO1999065940A1 (en) 1999-12-23

Similar Documents

Publication Publication Date Title
IL140239A0 (en) Anti-angiogenic proteins and methods of use thereof
AU8079901A (en) Promyostatin peptides and methods of using same
HUP0200414A2 (en) Interferon-betha fusion proteins and uses
EP1071706A4 (en) Rapidly degrading gfp-fusion proteins and methods of use
WO2003059257A8 (en) Anti-angiogenic proteins and fragmentsand methods of use thereof
AP2001002080A0 (en) Pilveriser and method of pulverising
AU1334602A (en) Osteopontin-coated surfaces and methods of use
GB9819898D0 (en) New vaccine and method of use
GB9804121D0 (en) Anti-angiogenic vaccines: materials and methods relating thereto
ZA985999B (en) Protein kinases and uses thereof
HUP9800146A3 (en) Thalidomide-derivatives and use of them
EP1263935A4 (en) Scytonemin and methods of using thereof
AU3964499A (en) Agouti-related protein analogs and methods of use
HUP0102850A2 (en) Methods and compositions for the determination of protein function and identification of modulators thereof
EP1142999A4 (en) Novel protein and dna thereof
AU2002214598A1 (en) Claspin proteins and methods of use thereof
EP1141269A4 (en) Secreted proteins and uses thereof
EP1111047A4 (en) Novel protein and dna thereof
GB9828346D0 (en) Protein and compositions containing it
EP1210111A4 (en) Gamma-herpesvirus dna and methods of use
HUP0003403A3 (en) Proteins having insecticidal activities and method of use
GB0002559D0 (en) Virulencegene and protein and their use
GB9828712D0 (en) Glycosylphosphatidylinositol specific phospholipase d proteins and usues thereof
EP1227149A4 (en) Novel protein and use thereof
GB9828359D0 (en) Protein and compositions containing it